Biogen (BIIB) Tops Q2 EPS by 127c; profit guidance raised
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) PT Raised to $292 at RBC Capital
August 2, 2024 6:24 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Biogen (NASDAQ: BIIB) to $292.00 (from $282.00) while maintaining a Outperform rating.
The analyst comments "BIIB's 2Q was better than today's stock action might suggest; while the beat was in partially driven by a few... More
Biogen (BIIB) tops Q2 expectations, raises profit guidance
August 1, 2024 7:27 AM EDTBiogen (NASDAQ: BIIB) reported its second-quarter results on Thursday, surpassing analyst expectations with an adjusted EPS of $5.28, significantly higher than the estimated $4.01.
The company's revenue also exceeded forecasts, coming in at $2.47 billion against a consensus estimate of $2.39 billion. Despite a flat year-over-year (YoY) total revenue, the adjusted EPS saw a notable 31% increase YoY.
The pharmaceutical giant's strong performance is reflected in its raised full-year... More
